- Home
- SAFE vs NEO Comparison
SAFE vs NEO Comparison
Compare SAFE & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- NEO
- Stock Information
- Founded
- SAFE 2016
- NEO 2001
- Country
- SAFE United States
- NEO United States
- Employees
- SAFE N/A
- NEO N/A
- Industry
- SAFE Real Estate Investment Trusts
- NEO Precision Instruments
- Sector
- SAFE Real Estate
- NEO Health Care
- Exchange
- SAFE Nasdaq
- NEO Nasdaq
- Market Cap
- SAFE 1.1B
- NEO 963.9M
- IPO Year
- SAFE 2017
- NEO 1999
- Fundamental
- Price
- SAFE $14.71
- NEO $6.29
- Analyst Decision
- SAFE Buy
- NEO Buy
- Analyst Count
- SAFE 9
- NEO 9
- Target Price
- SAFE $22.33
- NEO $13.31
- AVG Volume (30 Days)
- SAFE 397.2K
- NEO 1.5M
- Earning Date
- SAFE 08-05-2025
- NEO 07-29-2025
- Dividend Yield
- SAFE 4.80%
- NEO N/A
- EPS Growth
- SAFE N/A
- NEO N/A
- EPS
- SAFE 1.46
- NEO N/A
- Revenue
- SAFE $391,206,000.00
- NEO $672,361,000.00
- Revenue This Year
- SAFE $0.32
- NEO $13.97
- Revenue Next Year
- SAFE $5.07
- NEO $11.36
- P/E Ratio
- SAFE $10.09
- NEO N/A
- Revenue Growth
- SAFE 2.64
- NEO 10.10
- 52 Week Low
- SAFE $13.68
- NEO $6.08
- 52 Week High
- SAFE $28.80
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- SAFE 41.10
- NEO 34.53
- Support Level
- SAFE $14.65
- NEO $6.20
- Resistance Level
- SAFE $15.43
- NEO $6.66
- Average True Range (ATR)
- SAFE 0.41
- NEO 0.31
- MACD
- SAFE -0.05
- NEO -0.06
- Stochastic Oscillator
- SAFE 8.63
- NEO 5.56
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.